Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Stockholders' Equity (Unaudited)

v3.21.2
Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)
Series A Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Note Recievable For Common Stock Related Party [Member]
Retained Earnings [Member]
Total
BALANCES, April 30, 2020 at Apr. 30, 2020 $ 75 $ 6,476 $ 27,584,227 $ (14,983,200) $ (11,785,869) $ 821,709
Balance, beginning (in shares) at Apr. 30, 2020 750,000 64,762,858        
Stock-based compensation to employees and consultants 989,526 989,526
Net loss (2,670,849) (2,670,849)
BALANCES, October 31, 2020 at Oct. 31, 2020 $ 75 $ 6,476 28,666,695 (14,883,295) (14,456,718) (666,767)
Balance, end (in shares) at Oct. 31, 2020 750,000 64,762,858        
Proceeds from note receivable – related party for common stock 99,905 99,905
Fair value of warrants issued in connection with convertible notes 78,642 78,642
Fair value of warrants issued in connection with convertible notes - related party 14,300 14,300
BALANCES, April 30, 2020 at Jul. 31, 2020 $ 75 $ 6,476 28,090,238 (14,968,300) (13,102,621) 25,868
Balance, beginning (in shares) at Jul. 31, 2020 750,000 64,762,858        
Stock-based compensation to employees and consultants 483,515 483,515
Net loss (1,354,097) (1,354,097)
BALANCES, October 31, 2020 at Oct. 31, 2020 $ 75 $ 6,476 28,666,695 (14,883,295) (14,456,718) (666,767)
Balance, end (in shares) at Oct. 31, 2020 750,000 64,762,858        
Proceeds from note receivable – related party for common stock 85,005 85,005
Fair value of warrants issued in connection with convertible notes 78,642 78,642
Fair value of warrants issued in connection with convertible notes - related party 14,300 14,300
BALANCES, April 30, 2020 at Apr. 30, 2021 $ 75 $ 6,743 33,721,859 (14,883,295) (16,832,437) $ 2,012,945
Balance, beginning (in shares) at Apr. 30, 2021 750,000 67,429,525       67,429,525
Issuance of common stock for restricted stock awards $ 21 (21)
Issuance of common stock for restricted stock awards (in shares)           212,500
Stock-based compensation to employees and consultants 2,020,006 $ 2,020,006
Proceeds from stock option exercise $ 200 600 800
Proceeds from stock option exercise (in shares)   2,000,000        
Net loss (5,919,796) (5,919,796)
BALANCES, October 31, 2020 at Oct. 31, 2021 $ 8,885 50,652,054 (14,883,295) (22,752,233) 13,025,411
Balance, end (in shares) at Oct. 31, 2021   88,850,358        
Proceeds from sale of common stocks & warrants-related party $ 133 1,999,867 2,000,000
Proceeds from sale of common stocks and warrants-related party (in shares)   1,333,333        
Proceeds from initial public offering, net of underwriters’ discounts and commissions and issuance costs of $1.5 million $ 288 12,911,168 12,911,456
[custom:StockIssuedDuringPeriodSharesNewIssues3]   2,875,000        
Conversion of Series A convertible preferred stock $ (75) $ 1,500 (1,425)
Conversion of Series A convertible preferred stock (in shares) (750,000) 15,000,000        
BALANCES, April 30, 2020 at Jul. 31, 2021 $ 8,689 49,371,166 (14,883,295) (19,152,304) 15,344,256
Balance, beginning (in shares) at Jul. 31, 2021   86,887,858        
Issuance of common stock for restricted stock awards $ 21 (21)
Issuance of common stock for restricted stock awards (in shares)   212,500        
Stock-based compensation to employees and consultants 1,280,384 1,280,384
Proceeds from stock option exercise $ 175 525 700
Proceeds from stock option exercise (in shares)   1,750,000        
Net loss (3,599,929) (3,599,929)
BALANCES, October 31, 2020 at Oct. 31, 2021 $ 8,885 $ 50,652,054 $ (14,883,295) $ (22,752,233) $ 13,025,411
Balance, end (in shares) at Oct. 31, 2021   88,850,358